Hushmandi K, Einollahi B, Lee E, Sakaizawa R, Glaviano A, Reiter R
Int J Biol Sci. 2025; 21(4):1410-1435.
PMID: 39990653
PMC: 11844292.
DOI: 10.7150/ijbs.96155.
Fawcett C, Tickle J, Coles C
MAbs. 2024; 16(1):2311992.
PMID: 39674918
PMC: 10883111.
DOI: 10.1080/19420862.2024.2311992.
Gu Y, Zhao Q
Mol Diagn Ther. 2024; 28(6):669-702.
PMID: 39172329
PMC: 11512917.
DOI: 10.1007/s40291-024-00734-w.
Mohan N, Ayinde S, Peng H, Dutta S, Shen Y, Falkowski V
Front Immunol. 2024; 15:1376096.
PMID: 38863707
PMC: 11165055.
DOI: 10.3389/fimmu.2024.1376096.
Rubio A, Baharani V, Dadonaite B, Parada M, Abernathy M, Wang Z
bioRxiv. 2024; .
PMID: 38766244
PMC: 11100608.
DOI: 10.1101/2024.05.05.592584.
Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies.
Wirchnianski A, Nyakatura E, Herbert A, Kuehne A, Abbasi S, Florez C
PLoS Pathog. 2024; 20(4):e1012134.
PMID: 38603762
PMC: 11037526.
DOI: 10.1371/journal.ppat.1012134.
Design and engineering of bispecific antibodies: insights and practical considerations.
Madsen A, Pedersen L, Kristensen P, Goletz S
Front Bioeng Biotechnol. 2024; 12:1352014.
PMID: 38333084
PMC: 10850309.
DOI: 10.3389/fbioe.2024.1352014.
Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview.
Lan H, Chen M, Yao S, Chen J, Jin K
Front Immunol. 2023; 14:1266450.
PMID: 38111570
PMC: 10725925.
DOI: 10.3389/fimmu.2023.1266450.
Efficient production of bispecific antibodies-optimization of transfection strategy leads to high-level stable cell line generation of a Fabs-in-tandem immunoglobin.
Gong S, Wu C
Antib Ther. 2023; 6(3):170-179.
PMID: 37492586
PMC: 10365153.
DOI: 10.1093/abt/tbad013.
Applications of synthetic biology in medical and pharmaceutical fields.
Yan X, Liu X, Zhao C, Chen G
Signal Transduct Target Ther. 2023; 8(1):199.
PMID: 37169742
PMC: 10173249.
DOI: 10.1038/s41392-023-01440-5.
VERITAS: Harnessing the power of nomenclature in biologic discovery.
Biswas R, Belouski E, Graham K, Hortter M, Mock M, Tinberg C
MAbs. 2023; 15(1):2207232.
PMID: 37162235
PMC: 10173791.
DOI: 10.1080/19420862.2023.2207232.
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer.
Rabia E, Garambois V, Dhommee C, Larbouret C, Lajoie L, Buscail Y
Front Immunol. 2023; 14:1168444.
PMID: 37153618
PMC: 10157173.
DOI: 10.3389/fimmu.2023.1168444.
Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function.
Leung I, Templeton M, Lo Y, Rajan A, Stull S, Garrison S
Blood Adv. 2022; 7(12):2718-2730.
PMID: 36469024
PMC: 10275707.
DOI: 10.1182/bloodadvances.2022008559.
A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy.
Liu D, Qi X, Wei X, Zhao L, Wang X, Li S
Theranostics. 2022; 12(18):7788-7803.
PMID: 36451856
PMC: 9706591.
DOI: 10.7150/thno.75037.
Leveraging a Dual Variable Domain Immunoglobulin to Create a Site-Specifically Modified Radioimmunoconjugate.
MacPherson D, Hwang D, Sarrett S, Keinanen O, Rodriguez C, Rader C
Mol Pharm. 2022; 20(1):775-782.
PMID: 36377696
PMC: 10263003.
DOI: 10.1021/acs.molpharmaceut.2c00700.
The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics.
Khatib S, Salla M
Leuk Res Rep. 2022; 18:100335.
PMID: 35832747
PMC: 9272380.
DOI: 10.1016/j.lrr.2022.100335.
PD-L1/TIGIT bispecific antibody showed survival advantage in animal model.
Mu S, Liang Z, Wang Y, Chu W, Chen Y, Wang Q
Clin Transl Med. 2022; 12(5):e754.
PMID: 35522941
PMC: 9076010.
DOI: 10.1002/ctm2.754.
Synthesis of Multiple Bispecific Antibody Formats with Only One Single Enzyme Based on Enhanced Trypsiligase.
Voigt J, Meyer C, Bordusa F
Int J Mol Sci. 2022; 23(6).
PMID: 35328563
PMC: 8952323.
DOI: 10.3390/ijms23063144.
Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of 'Almost Natural' Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection.
Klewinghaus D, Pekar L, Arras P, Krah S, Valldorf B, Kolmar H
Front Immunol. 2022; 12:801368.
PMID: 35087526
PMC: 8787767.
DOI: 10.3389/fimmu.2021.801368.
Engineering pan-HIV-1 neutralization potency through multispecific antibody avidity.
Rujas E, Cui H, Burnie J, Aschner C, Zhao T, Insausti S
Proc Natl Acad Sci U S A. 2022; 119(4).
PMID: 35064083
PMC: 8795538.
DOI: 10.1073/pnas.2112887119.